Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
dc.contributor.authorAGUERRECHE, Clément
dc.contributor.authorCADIER, Gaspard
dc.contributor.authorBEURTON, Antoine
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorIMBAULT, Julien
dc.contributor.authorLEUILLET, Sébastien
dc.contributor.authorREMY, Alain
dc.contributor.authorZAOUTER, Cédrick
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorOUATTARA, Alexandre
dc.date.accessioned2023-01-10T09:37:44Z
dc.date.available2023-01-10T09:37:44Z
dc.date.issued2021-06-03
dc.identifier.issn1471-2253en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/171642
dc.description.abstractEnNo previous study investigated the dexmedetomidine-based opioid-free anesthesia (OFA) protocol in cardiac surgery. The main objective of this study was to evaluate the feasibility and the postoperative opioid-sparing effect of dexmedetomidine-based OFA in adult cardiac surgery patients. We conducted a single-centre and retrospective study including 80 patients above 18 years old who underwent on-pump cardiac surgery between November 2018 and February 2020. Patients were divided into two groups: OFA (lidocaine, ketamine, dexmedetomidine, MgSO4) or opioid-based anaesthesia (remifentanil and anti-hyperalgesic medications such as ketamine and/or MgSO4 and/or lidocaine at the discretion of the anesthesiologist). The primary endpoint was the total amount of opioid consumed in its equivalent of intravenous morphine during the first 48 postoperative hours. Secondary outcomes included perioperative hemodynamics, post-operative maximal pain at rest and during coughing and adverse outcomes. Data are expressed as median [interquartile range]. Patients in the OFA-group had a higher EuroSCORE II, with more diabetes, more dyslipidemia and more non-elective surgery but fewer smoking history. In the OFA group, the median loading dose of dexmedetomidine was 0.6 [0.4-0.6] μg.kg while the median maintenance dose was 0.11 μg.kg.h [0.05-0.20]. In 10 (25%) patients, dexmedetomidine was discontinued for a drop of mean arterial pressure below 55 mmHg. The median total amount of opioid consumed in its equivalent of intravenous morphine during the first 48 postoperative hours was lower in the OFA group (15.0 mg [8.5-23.5] versus 30.0 mg [17.3-44.3], p < 0.001). While no differences were seen with rest pain (2.0 [0.0-3.0] versus 0.5 [0.0-5.0], p = 0.60), the maximal pain score during coughing was lower in OFA group (3.5 [2.0-5.0] versus 5.5 [3.0-7.0], p = 0.04). In OFA group the incidence of atrial fibrillation (18% versus 40%, p = 0.03) and non-invasive ventilation use (25% versus 48%, p = 0.04) were lower. The incidence of bradycardia and the intraoperative use of norepinephrine were similar between both groups. Dexmedetomidine-based OFA in cardiac surgery patients is feasible and could be associated with a lower postoperative morphine consumption and better postoperative outcomes. Further randomized studies are required to confirm these promising results and determine the optimal associations, dosages, and infusion protocols during cardiac surgery.
dc.language.isoENen_US
dc.subject.enAged
dc.subject.enAnalgesics
dc.subject.enOpioid
dc.subject.enAnesthesia
dc.subject.enCardiac Surgical Procedures
dc.subject.enDexmedetomidine
dc.subject.enFeasibility Studies
dc.subject.enFemale
dc.subject.enFrance
dc.subject.enHumans
dc.subject.enHypnotics and Sedatives
dc.subject.enMale
dc.subject.enMiddle Aged
dc.subject.enPain
dc.subject.enPostoperative
dc.subject.enRetrospective Studies
dc.title.enFeasibility and postoperative opioid sparing effect of an opioid-free anaesthesia in adult cardiac surgery: a retrospective study.
dc.title.alternativeBMC Anesthesiolen_US
dc.typeArticle de revueen_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed34082712en_US
bordeaux.journalBMC Anesthesiologyen_US
bordeaux.page166en_US
bordeaux.volume21en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=BMC%20Anesthesiology&amp;rft.date=2021-06-03&amp;rft.volume=21&amp;rft.issue=1&amp;rft.spage=166&amp;rft.epage=166&amp;rft.eissn=1471-2253&amp;rft.issn=1471-2253&amp;rft.au=AGUERRECHE,%20Cl%C3%A9ment&amp;CADIER,%20Gaspard&amp;BEURTON,%20Antoine&amp;IMBAULT,%20Julien&amp;LEUILLET,%20S%C3%A9bastien&amp;rft.genre=article


Archivos en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem